🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT03820492
Recruiting Not applicable

Comparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT

NCT03820492 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2019-05-28
Last updated
2023-02-09

Condition(s) studied

Coronary Stenosis

Investigational drug(s) / intervention(s)

OCT, FFR, CTA and FFRCT

OCT, FFR, CTA and FFRCT: Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT

Study summary

Significant left main (LM) stenosis is associated with a poor prognosis, therefore, adequate judgement of the prognostic significance of LM stenosis is essential to improve patients' prognosis. Recently, fractional flow reserve (FFR) has become widespread practice and carries a Class Ia recommendation to assess functional significance of intermediate coronary stenosis in patients with stable angina. Intravascular ultrasound (IVUS)-derived minimum lumen area (MLA) represents an accurate measure to determine LM significance as shown in multiple studies, while optical coherence tomography (OCT) ,which is a novel intracoronary imaging method with a greater spatial resolution (15μm vs. 100μm), faster image acquisition and facilitated image interpretation, OCT derived-MLA has never been validated against FFR and accordingly, it is not mentioned in the current guidelines for myocardial revascularization. Coronary computed tomography angiography (CTA) has emerged as a noninvasive alternative of coronary angiography with its excellent negative predictive value, while the positive predictive value of CTA is limited. Computational fluid dynamics is an emerging method that enables prediction of blood flow in coronary arteries and calculation of FFR from computed tomography (FFRCT) noninvasively. Noninvasive and accurate assessment of functional significance would bring a great benefit for patients with LM stenosis, however, there are no data to evaluate the diagnostic accuracy of FFRCT for LM stenosis in comparison with FFR and minimal lumen area derived by OCT.

This study will investigate the optimal OCT-derived MLA cut-off point and the diagnostic performance of FFRCT for intermediate LM stenosis compared with FFR ≤0.8 as a reference standard.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Unprotected LM lesion \[midshaft, and distal bifurcation (Medina 1,1,1 or 1,1,0 or 1,0,1 or 1,0,0)\] of 30% to 80% angiographic diameter stenosis (DS) on visual estimation or equivocal disease by angiography. * Age ≥18 years. * Ability to give preliminary oral consent witnessed by an independent physician or sign written informed consent prior to any study-specific procedures. Exclusion Criteria: * Significant distal lesions (\>50% angiographic DS on visual estimation within the left anterior descending artery \[LAD\] or left circumflex artery \[LCX\], except for ostium of LAD or LCX or diseased side branch \[e.g. diagonal branch, obtuse marginal branch\]) * Ostial LM disease. * Acute coronary syndrome (ACS) (non-ST-elevation ACS and ST-elevation MI). * LM In-stent restenosis. * Previous coronary stenting of the left coronary system. * Chronic total occlusion. * Previous coronary artery bypass graft. * Previous MI related to the left coronary artery. * Occurrence of ventricularization or hypotension during engagement of the LM ostial lesion. * The presence of hemodynamic instability. * Known renal insufficiency (serum creatinine \>1.5mg/dL or receiving dialysis). * Female of childbearing potential (age \<50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy. * Life expectancy less than 1 year. * Contraindication or known allergy against protocol-required medications including heparin, iodinated contrast, β-blocker, nitroglycerin, and adenosine. * Body mass index \>35kg/m2. * Complex congenital heart disease other than anomalous coronary origins alone. * Ventricular septal defect.

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
Centre Hospitalier Universitaire de Clermont-Ferrand Clermont-Ferrand France Recruiting
Institute Mutualiste Montsouris Paris France Recruiting
Centre Cardiologique du Nord Saint-Denis France Recruiting
Universitätsklinikum Giessen Justus-Liebig Universität Giessen Hesse Recruiting
Friedrich Alexander Universität (FAU) , Medizinische Klinik 2 , Kardiologie und Angiologie Erlangen Germany Recruiting
Ageo Central General Hospital Ageo Japan Recruiting
Gifu heart center Gifu Japan Recruiting
Department of Cardiovascular Medicine Shinshu University School of Medicine Nagano Japan Recruiting
Kansai Medical University, Osaka Japan Recruiting
Medical Corporation Ouyuukai Tokorozawa Heart Center Saitama Japan Recruiting
Sapporo Higashi Tokushukai Hospital Sapporo Japan Recruiting
Inselspital Bern Switzerland Recruiting
CHUV Lausanne Switzerland Recruiting

More Insel Gruppe AG, University Hospital Bern trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03820492 on ClinicalTrials.gov ↗ ← All trials in Germany